This most frequently manifests as mutations in the KRAS, NRAS, and BRAF genes.[9,10] RAS mutations have been found in one-third of all cancers, of which KRAS mutations are the most prevalent (>80%) whereas mutations in NRAS (approximately 10%) and HRAS (<5%) are relatively rare. This evidence concerns the gene NRAS and cancer.